Therein, afatinib, a drug for non-small cell lung cancer, achieved its therapeutic goal through potent, irreversible dual inhibition of EGFR and HER2 tyrosine kinases [37, 38]. Here, ERBB2 is linked to non-small cell lung carcinoma.